GFP-BRD2 Citations (6)
Originally described in: Screen identifies bromodomain protein ZMYND8 in chromatin recognition of transcription-associated DNA damage that promotes homologous recombination.Gong F, Chiu LY, Cox B, Aymard F, Clouaire T, Leung JW, Cammarata M, Perez M, Agarwal P, Brodbelt JS, Legube G, Miller KM Genes Dev. 2015 Jan 15;29(2):197-211. doi: 10.1101/gad.252189.114. PubMed Journal
Articles Citing GFP-BRD2
| Articles |
|---|
| The Pioneering Role of GATA2 in Androgen Receptor Variant Regulation Is Controlled by Bromodomain and Extraterminal Proteins in Castrate-Resistant Prostate Cancer. Chaytor L, Simcock M, Nakjang S, Heath R, Walker L, Robson C, Jones D, Gaughan L. Mol Cancer Res. 2019 Jun;17(6):1264-1278. doi: 10.1158/1541-7786.MCR-18-1231. Epub 2019 Mar 4. PubMed |
| Functional Analysis of the Replication Fork Proteome Identifies BET Proteins as PCNA Regulators. Wessel SR, Mohni KN, Luzwick JW, Dungrawala H, Cortez D. Cell Rep. 2019 Sep 24;28(13):3497-3509.e4. doi: 10.1016/j.celrep.2019.08.051. PubMed |
| PCNA Unloading Is Negatively Regulated by BET Proteins. Kang MS, Kim J, Ryu E, Ha NY, Hwang S, Kim BG, Ra JS, Kim YJ, Hwang JM, Myung K, Kang S. Cell Rep. 2019 Dec 24;29(13):4632-4645.e5. doi: 10.1016/j.celrep.2019.11.114. PubMed |
| Viral E protein neutralizes BET protein-mediated post-entry antagonism of SARS-CoV-2. Chen IP, Longbotham JE, McMahon S, Suryawanshi RK, Khalid MM, Taha TY, Tabata T, Hayashi JM, Soveg FW, Carlson-Stevermer J, Gupta M, Zhang MY, Lam VL, Li Y, Yu Z, Titus EW, Diallo A, Oki J, Holden K, Krogan N, Fujimori DG, Ott M. Cell Rep. 2022 Jul 19;40(3):111088. doi: 10.1016/j.celrep.2022.111088. Epub 2022 Jun 27. PubMed |
| Identification of Human Host Substrates of the SARS-CoV-2 M(pro) and PL(pro) Using Subtiligase N-Terminomics. Luo SY, Moussa EW, Lopez-Orozco J, Felix-Lopez A, Ishida R, Fayad N, Gomez-Cardona E, Wang H, Wilson JA, Kumar A, Hobman TC, Julien O. ACS Infect Dis. 2023 Apr 14;9(4):749-761. doi: 10.1021/acsinfecdis.2c00458. Epub 2023 Apr 3. PubMed |
| DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia. Ali I, Cha HJ, Lim B, Chae CH, Youm J, Park WJ, Lee SH, Kim JH, Jeong D, Lim JK, Hwang YH, Roe JS, Woo JS, Lee K, Choi G. Eur J Med Chem. 2024 Feb 5;265:116052. doi: 10.1016/j.ejmech.2023.116052. Epub 2023 Dec 16. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.